MeiraGTx Holdings plc Expense Breakdown
No Expense Breakdown for MGTX on this site yet.
- 2026-06-30: Single Reportable $2.83M.
- 2025-06-30: Single Reportable $3.19M.
Source checked: the stored Expense Breakdown page for MGTX.
Expenses by product
Depreciation, Depletion and Amortization: each quarter (3 month)
| Quarter end | Single Reportable |
|---|---|
| 2026-06-30 | $2.83M |
| 2025-06-30 | $3.19M |
Operating expenses: each quarter (3 month)
| Quarter end | Single Reportable |
|---|---|
| 2026-06-30 | $77.01M |
| 2025-06-30 | $48.48M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |